Wells Fargo analyst Joseph O’Dea lowered the firm’s price target on Emerson (EMR) to $140 from $145 and keeps an Overweight rating on the shares. The firm thinks initial 2025 guidance in the space will drive negative revisions in consensus estimates. Recent dollar strength is a large driver of the headwind, Wells adds, noting that it believes currency pressure is largely appreciated, so initial guidance ranges below consensus shouldn’t come as a big surprise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: